Objectives
Given the rare and aggressive nature of (m)UM, there are limited data characterising the disease and treatment pathway of patients to inform an understanding of standard of care (SoC).
To inform a real-world understanding of (m)UM SoC treatment pathways, this study aimed to: 1) Identify a cohort of (m)UM patients within the NHSE monopsony, using the HES database [5] . 2) Compare characteristics and observations of the HES cohort against the published literature and modelled epidemiological estimates.
Methods
Within the HES dataset (observational period: April 2012-March 2017), we identified a cohort of UM patients with malignant neoplasms of the choroid, ciliary body and iris (ICD-10: C69.3, C69.4), and no other prior cancer code [5] .
Of these identified UM patients, we then selected a cohort that subsequently experienced a noneye-related cancer code during the observational period, that was clinically characteristic of a UM metastasis ( [6] , Table 3 ). This was considered to give a conservative estimate of the occurrence of metastasis in the overall UM cohort.
Patients with an unspecified (C69.9) or benign (D31) neoplasm of the eye at their first inpatient admission followed by a C693 or C694 in later admissions, were also included if they had a subsequent liver metastasis (C787).
To identify the expected incidence of mUM in the cohort, we developed an epidemiological model.
UK-specific incidence data for eye cancer (ICD-10 code: C69) were identified within national statistics reports [8] and a ratio of choroid, ciliary body and iris involvement (C69.3 and C69.4 with melanoma ICD-O-3 histology code range 8720-8790) were applied from a comprehensive US cancer registry [9] , to derive age-specific and gender-specific incidence of primary UM in the UK. These UM incidence cases were then segmented by disease stage (I, II, III, and IV) at initial diagnosis [10, 11] .
Using registry data for UM patients observed for 0-10 years [12] and >10 years [6] prior to their metastatic (mUM) diagnosis, an annual incidence of metastatic progression ("recurrence") from an originating stage I-III diagnosis were then derived. These were further adjusted for age and gender distribution to enable an adjusted annual estimate of "recurrence".
The expected total number of mUM ("recurrence" + stage IV) patients within the NHSE population of (54.786 M persons in 2015) was then estimated.
Patient characteristics were extracted from HES and descriptively analysed. These data were then compared to published literature [1] [2] [3] [4] [5] [6] [7] and the expected incidence population (epidemiological model) to validate the cohort as being a (m)UM cohort for future evaluation.
Results and Validation of the Cohort
Over the observational period, we identified a cohort of 2,484 UM patients within HES ( Table 1) .
501 patients in this cohort were diagnosed with mUM ( Table 2 ).
The clinical characteristics of both the UM and mUM patients in these HES cohorts were considered similar to those reported in the literature ( Table 1 and Table 2 ).
The median time from UM to first mUM diagnosis was 283 days (range 0 -1675).
Conclusions
The epidemiological and clinical characteristics of our (m)UM cohorts identified within HES appear consistent with modelled estimates and are validated by the published literature.
This methodology enables a deeper insight into SoC treatment pathways and understanding of real world outcomes associated with an (ultra) rare disease [13] , such as UM.
Alongside the future introduction of an effective treatment, this methodology potentially provides the ability to assist with identifying, measuring, and coordinating the care pathway to ultimately improve outcomes for mUM patients. 
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Discussion
Recognising the limitations and the 'intent of data capture' when using any observational database; alongside the spontaneous nature of metastases; for a small rare disease population; and the recent improvements in surveillance for metastatic disease [1] , the number of identified (m)UM patients in the HES cohort would be broadly consistent with expected estimates for the population.
The disease characteristics of the UM and mUM patients identified in the HES cohort are also broadly comparable to the published data.
In our HES data, new mUM attendances increased over time ( Figure 1B) ; this is likely a function of the length of time a patient in the cohort is observed.
There was slightly less overall liver involvement in our cohort (Table 3) , which could be due to a limited follow-up period (<4 years for most patients), compared to the >5-year data reported [6] .
There were also more skin/soft tissue metastases compared to other cohorts, which may be due to local variances in coding definitions for soft tissue involvement.
National UM guidelines [1] introduced in 2015 and improved surveillance methods may explain the observed increase in the initial detection and rate of identifying liver metastasis during a patient's 1 st year of having UM diagnosis, in the later years of the HES cohort ( Figure 2 ). Presented at ISPOR 2017, Glasgow, UK. PRM3
The incidence of UM was stable over time; with 224 new patients on average being diagnosed every 6 months (range 212 -286) ( Figure 1A) .
In applying the reported annual incidence of new UM cases (6 to 10 per million UK persons [1, 2] ) to the population of NHSE, 329 to 548 new UM patients would be expected in 2015, respectively.
In our HES cohort, 481 new UM patients were identified in 2015 (Figure 1a ) -equivalent to an incidence of 8.8 per million of the NHSE population
In applying our epidemiology model to the NHSE population, 118 new mUM patients would be expected in 2015.
In our HES cohort, we identified 129 mUM patients in 2015 (Figure 1b) .
Consistent with the literature, the liver had the most metastatic involvement (67%), and was the most common site of first metastasis for mUM patients ( Table 3) .
In later years (2014-2015), more patients in the HES dataset had admissions for liver metastasis in their first year following a UM diagnosis, compared to earlier years (2012-2013) (Figure 2 ).
